参考文献/References:
[1] MARTIN-LOECHES I,RODRIGUEZ A H,TORRES A.New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia:USA vs.Europe[J].Curr Opin Crit Care,2018,24(5):347-352.
[2] XU Y,LAI C Y,XU G G,et al.Risk factors of ventilator-associated pneumonia in elderly patients receiving mechanical ventilation[J].Clin Interv Aging,2019,14(5):1027-1038.
[3] YAO J,GUAN S H,LIU Z,et al.Changes in immune indicators and bacteriologic profile were associated with patients with ventilator-associated pneumonia[J].Medicine,2020,99(16):e19716.
[4] CORBACHO R E M F,ROCCHETTI N S,SETTECASE C J,et al.Diagnostic value of procalcitonin in ventilator-associated pneumonia[J].Med Clin,2019,152(6):216-221.
[5] SUN Y L,ZHAO T X,LI D,et al.Predictive value of C-reactive protein and the pediatric risk of mortality III score for occurrence of postoperative ventilator-associated pneumonia in pediatric patients with congenital heart disease[J].Pediatr Investig,2019,3(2):91-95.
[6] 中华医学会重症医学分会.呼吸机相关性肺炎诊断、预防和治疗指南(2013)[J].中华内科杂志,2013,52(6):524-543.
INTENSIVE MEDICINE BRANCH OF THE CHINESE MEDICAL ASSOCIATION.Guidelines for the diagnosis,prevention and treatment of ventilator-associated pneumonia (2013)[J].Chin J Intern Med,2013,52(6):524-543.
[7] KALLET R H.Ventilator bundles in transition:from prevention of ventilator-associated pneumonia to prevention of ventilator-associated events[J].Respir Care,2019,64(8):994-1006.
[8] ZHU Y G,MONSEL A,ROBERTS J A,et al.Nebulized colistin in ventilator-associated pneumonia and tracheobronchitis:historical background,pharmacokinetics and perspectives[J].Microorganisms,2021,9(6):1154-1162.
[9] BASSETTI M,MULARONI A,GIACOBBE D R,et al.New antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia[J].Semin Respir Crit Care Med,2022,43(2):280-294.
[10] ALECRIM R X,TAMINATO M,BELASCO A,et al.Strategies for preventing ventilator-associated pneumonia:an integrative review[J].Rev Bras Enferm,2019,72(2):521-530.
[11] PATHAK K V,MCGILVREY M I,HU C K,et al.Molecular profiling of innate immune response mechanisms in ventilator-associated pneumonia[J].Mol Cell Proteomics,2020,19(10):1688-1705.
[12] 沈业周,张俭,余娇阳,等.老年呼吸机相关性肺炎患者炎症因子、乳酸、和肽素及免疫功能的变化[J].中国卫生检验杂志,2020,30(3):316-318.
SHEN Y Z,ZHANG J,YU J Y,et al.Changes of inflammatory factors,lactic acid,peptide and immune function in elderly patients with ventilator-associated pneumonia[J].Chin J Health Inspect,2020,30 (3):316-318.
[13] ZHOU J,SONG J,GONG S,et al.Lung ultrasound combined with procalcitonin for a diagnosis of ventilator-associated pneumonia[J].Respir Care,2019,64(5):519-527.
[14] 贾向红,刘亚博,周志敏.呼吸机相关性肺炎患者病原菌分布及血清降钙素原和白细胞介素-6水平对其预后的预测价值[J].新乡医学院学报,2021,38(12):1155-1159.
JIA X H,LIU Y B,ZHOU Z M.The prognostic value of pathogenic bacteria distribution and serum procalcitonin and interleukin-6 levels in patients with ventilator-associated pneumonia[J].J Xinxiang Med Univ,2021,38 (12):1155-1159.
[15] CHEN C Q,YAN M,HU C,et al.Diagnostic efficacy of serum procalcitonin,C-reactive protein concentration and clinical pulmonary infection score in ventilator-associated pneumonia[J].Med Sci,2018,34 (1):26-32.
相似文献/References:
[1]宋庆梅.小儿呼吸机相关性肺炎病原菌分布及耐药性分析[J].新乡医学院学报,2012,29(08):628.
[2]高 飞 综述,严 洁 审校.呼吸机相关性肺炎诊断与治疗新进展 [J].新乡医学院学报,2012,29(10):809.
[3]贾向红,刘亚博,周志敏.呼吸机相关性肺炎患者病原菌分布及血清降钙素原和白细胞介素-6水平对其预后的预测价值[J].新乡医学院学报,2021,38(12):1155.[doi:10.7683/xxyxyxb.2021.12.010]
JIA Xianghong,LIU Yabo,ZHOU Zhimin.Distribution of pathogenic bacteria and the value of serum procalcitonin and interleukin-6 levels in predicting the prognosis of patients with ventilator-associated pneumonia[J].Journal of Xinxiang Medical University,2021,38(5):1155.[doi:10.7683/xxyxyxb.2021.12.010]